Sargent Bickham Lagudis’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sargent Bickham Lagudis’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$4.15K	Buy	+50	New	+$4.05K	﹤0.01%	825
2022 Q2	–	Sell	-100	Closed	-$9K	–	1150
2022 Q1	$9K	Hold	100	–	–	﹤0.01%	735
2021 Q4	$11K	Hold	100	–	–	﹤0.01%	704
2021 Q3	$13K	Hold	100	–	–	﹤0.01%	682
2021 Q2	$14K	Hold	100	–	–	﹤0.01%	668
2021 Q1	$14K	Hold	100	–	–	﹤0.01%	645
2020 Q4	$14K	Buy	100 +15	+18%	+$1.92K	﹤0.01%	614
2020 Q3	$9K	Buy	85 +20	+31%	+$2.24K	﹤0.01%	614
2020 Q2	$7K	Buy	65 +30	+86%	+$2.96K	﹤0.01%	619
2020 Q1	$3K	Buy	+35	New	+$3.1K	﹤0.01%	689
2018 Q4	–	Sell	-1,647	Closed	-$158K	–	807
2018 Q3	$158K	Hold	1,647	–	–	0.02%	228
2018 Q2	$157K	Hold	1,647	–	–	0.02%	228
2018 Q1	$144K	Hold	1,647	–	–	0.02%	244
2017 Q4	$140K	Hold	1,647	–	–	0.02%	250
2017 Q3	$143K	Hold	1,647	–	–	0.02%	248
2017 Q2	$127K	Hold	1,647	–	–	0.02%	245
2017 Q1	$114K	Hold	1,647	–	–	0.01%	259
2016 Q4	$97K	Hold	1,647	–	–	0.02%	266
2016 Q3	$109K	Hold	1,647	–	–	0.02%	262
2016 Q2	$89K	Hold	1,647	–	–	0.01%	279
2016 Q1	$85K	Buy	+1,647	New	+$85.5K	0.01%	291

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

APF

Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Sargent Bickham Lagudis's XBI Position: Q4 2022 in Review

Sargent Bickham Lagudis opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2022: 50 shares worth $4.15K. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Sargent Bickham Lagudis previously reported a position in XBI as recently as Q1 2022.

Sargent Bickham Lagudis first reported a position in XBI in Q1 2016 and has held it in 21 quarters since. The position peaked at $158K in Q3 2018. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2022.

Sargent Bickham Lagudis held 50 shares of State Street SPDR S&P Biotech ETF worth $4.15K as of Q4 2022.
State Street SPDR S&P Biotech ETF was a new Sargent Bickham Lagudis position in Q4 2022.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Sargent Bickham Lagudis's portfolio in Q4 2022, its #825 holding.
Sargent Bickham Lagudis first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 21 quarters since.
Sargent Bickham Lagudis's State Street SPDR S&P Biotech ETF position peaked at $158K in Q3 2018.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2022.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2022, filed 23 Jan 2023.